Summary
Vertex Pharmaceuticals Inc. (VRTX) reported its financial results for the quarter ending June 30, 2010. The company experienced a significant increase in total revenues, driven by strong growth in collaborative revenues, largely due to an amendment with Mitsubishi Tanabe Pharma Corporation and ongoing reimbursements from Janssen Pharmaceutica, N.V. for the development of telaprevir. Despite the revenue growth, Vertex continued to incur substantial net losses. This was primarily attributed to significant investments in research and development, particularly for telaprevir and VX-770 (cystic fibrosis program), and increasing sales, general, and administrative expenses in preparation for potential product launches. The company's cash, cash equivalents, and marketable securities saw a decrease, reflecting these operational expenditures. Vertex is advancing its lead drug candidate, telaprevir, through its registration program with an expected NDA submission in the second half of 2010 and potential US launch in 2011. The company anticipates needing to raise additional capital to fund its ongoing development and commercialization efforts.
Financial Highlights
44 data points| Revenue | $31.62M |
| Cost of Revenue | $0 |
| Gross Profit | $31.62M |
| R&D Expenses | $155.08M |
| SG&A Expenses | $40.91M |
| Operating Expenses | $201.19M |
| Operating Income | -$169.57M |
| Interest Expense | $3.68M |
| Net Income | -$200.01M |
| EPS (Basic) | $-1.00 |
| EPS (Diluted) | $-1.00 |
| Shares Outstanding (Basic) | 200.40M |
| Shares Outstanding (Diluted) | 200.40M |
Key Highlights
- 1Total revenues increased by 66% year-over-year to $31.6 million for the quarter, driven by a 85% surge in collaborative revenues.
- 2Research and development expenses increased by 11% to $155.1 million, reflecting continued investment in late-stage drug development, notably for telaprevir and VX-770.
- 3Sales, general, and administrative expenses rose by 26% to $40.9 million, indicating preparations for potential commercialization activities.
- 4The company reported a net loss of $200.0 million for the quarter, an increase from $171.3 million in the prior year period.
- 5Cash, cash equivalents, and marketable securities decreased by $305.8 million to $979.1 million compared to the end of the prior year.
- 6Vertex expects to complete its New Drug Application (NDA) submission for telaprevir in the second half of 2010, with a potential launch in 2011.
- 7The company's lead cystic fibrosis drug candidate, VX-770, is in its registration program with an anticipated NDA filing in the second half of 2011.